European Association of Urology Guidelines on Renal Transplantation: Update 2024

The European Association of Urology (EAU) Panel on Renal Transplantation released an updated version of the renal transplantation (RT) guidelines. This report aims to present the 2024 EAU guidelines on RT.

A broad and comprehensive scoping exercise covering all areas of RT guidelines published between May 31, 2020 and April 1, 2023 was performed. Databases covered by the search included Medline, Embase, and the Cochrane Libraries. Previous guidelines were updated, and levels of evidence and grades of recommendation were assigned.

It is strongly recommended to offer pure or hand-assisted laparoscopic/retroperitoneoscopic surgery for living donor nephrectomy. One should not base decisions regarding the acceptance of a donor organ on histological findings alone, since this might lead to an unnecessary high rate of discarded grafts. For the ureterovesical anastomosis, a Lich-Gregoir-like extravesical technique protected by a ureteral stent is the preferred technique. A list of RT patients with a history of appropriately treated low-stage/grade renal cell carcinoma or prostate cancer should be made without additional delay. In the potential donor kidney, the main surgical tumoral approach is ex vivo tumor excision and finally transplantation. It is also strongly recommended to perform initial rejection prophylaxis with a combination therapy of a calcineurin inhibitor (preferably tacrolimus), mycophenolate, steroids, and an induction agent (either basiliximab or antithymocyte globulin). The long version of the guidelines is available at the EAU website (www.uroweb.org/guidelines).

These abridged EAU guidelines present updated information on the clinical and surgical management of RT for incorporation into clinical practice.

The European Association of Urology has released the renal transplantation guidelines. Implementation of minimally invasive surgery for organ retrieval and the latest evidence on transplant surgery as well as on immunosuppressive regimens are key to minimizing rejection and achieving long-term graft survival.